The show that helps you maximize your wealth by turning complex financial situations into actionable advice. On Your Money. Your Mission., we answer the questions you’ve been asking about -- financial planning, investing, retirement and everything in between. Whether you’re navigating the complexities of the market or looking for the best ways to save or spend your money, tune in to hear from experienced financial advisors with JFG. Walk away from each episode with savvy tips and financial t ...
…
continue reading
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Medicus Pharma receives UAE approval to begin Phase 2 study for non-invasive BCC treatment
MP3•Episode home
Manage episode 484276212 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive that the company has received regulatory approval from the UAE Department of Health to proceed with its Phase 2 clinical trial (SKNJCT-004) for the non-invasive treatment of basal cell carcinoma (BCC) of the skin. The study will enroll 36 patients across four sites in the UAE: Cleveland Clinic Abu Dhabi, Sheikh Shakhbout Medical City, Burjeel Medical City, and American Hospital of Dubai. SKNJCT-004 is a randomized, double-blind, placebo-controlled, multi-center study designed to evaluate the efficacy of two dose levels of D-MNA (Dermal Micro-Needle Array) compared to placebo. Participants will be randomly assigned in a 1:1:1 ratio to receive either a placebo (P-MNA), 100μg of D-MNA (low dose), or 200μg of D-MNA (high dose) The 200μg dose was previously tested as the maximum dose in Medicus Pharma’s Phase 1 safety and tolerability study (SKNJCT-001), completed in March 2021. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation
…
continue reading
605 episodes
MP3•Episode home
Manage episode 484276212 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive that the company has received regulatory approval from the UAE Department of Health to proceed with its Phase 2 clinical trial (SKNJCT-004) for the non-invasive treatment of basal cell carcinoma (BCC) of the skin. The study will enroll 36 patients across four sites in the UAE: Cleveland Clinic Abu Dhabi, Sheikh Shakhbout Medical City, Burjeel Medical City, and American Hospital of Dubai. SKNJCT-004 is a randomized, double-blind, placebo-controlled, multi-center study designed to evaluate the efficacy of two dose levels of D-MNA (Dermal Micro-Needle Array) compared to placebo. Participants will be randomly assigned in a 1:1:1 ratio to receive either a placebo (P-MNA), 100μg of D-MNA (low dose), or 200μg of D-MNA (high dose) The 200μg dose was previously tested as the maximum dose in Medicus Pharma’s Phase 1 safety and tolerability study (SKNJCT-001), completed in March 2021. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation
…
continue reading
605 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.